Novavax coronavirus vaccine that was found to be 89.3% effective in a UK trial, its Chief Executive Officer Adar Poonawalla told news agency Reuters on Friday.Earlier today, Novavax said that its Covid-19 vaccine was 89.3% effective in preventing the killer virus in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in Britain, as per a preliminary analysis.Also Read | Covid vaccination faces slow startNovavax is reportedly stockpiling Covid-19 vaccines at six operating manufacturing sites and said it expects a total of eight plants in seven countries to produce at the rate of 2 billion doses per year, including from the SII, a major player in the.